

# **\$**URGO

# GLASGOW UNIVERSITY MEDICAL STUDENT Visual abstracts

**Is post-op radiotherapy correlated with the failure of dental implants in DCIA free flaps?** Devansh Shah, MBChB5




**Tobacco town Glasgow: Computational modelling of policies to reduce tobacco retailer density.** William Strachan, MBChB4






# GLASGOW UNIVERSITY MEDICAL STUDENT Visual abstracts

The experience of cerebral venous sinus thrombosis in children treated at the Royal Hospital for Children Glasgow. Monica Blair, MBChB5




The association between sleep quality and duration with cerebrovascular health: A UK biobank study.

Reuben Heaton, MBChB4



# GLASGOW UNIVERSITY MEDICAL STUDENT Visual abstracts

**Review of multiple birth minimisation strategy at Glasgow Assisted Conception Service.** Caitlin Mather, MBChB4





# MONEY MONEY MONEY Competition Time

Now that Surgo is linked to a Creative Commons license AND articles are regarded as citable publications, we want to give students the opportunity to share their research projects with the world. In each issue we want to publish five student visual abstracts.

#### What is a visual abstract?

A visual abstract is a novel way of presenting research. It is a small graphic that gives a brief overview of the research question, methods and conclusions of the project. In essence it is an eye catching summary of the research you have carried out. Below is an example published by the BMJ(1):

the <b>bmj</b> Visual abs	stract				atic breast trastuzumab ar	
Summary	First line pyrotinib with trastuzumab and docetaxel significantly improved progression-free survival, with a 13.9 month increase and a 59% reduction in the risk of disease progression or death					
🖉 Study design	$\prec$	Randomised controlled trial   🚧 Double blind   Phase 3 trial				
iii Population	80	590 female patients with untreated HER2 positive metastatic breast cancerMedian age 52 years				Location: China
Comparison	Pyrotinib with trastuzumab and docetaxel \$ 297		Control Placebo with trastuzumab and docetaxel i 293 ession-free survival per in		A set lease mo	anths 95% (1 -
Pyrotinib		0	12		24	36
Placebo						
Subgroup analysis			0.1	0.2 Haza	rd ratio 95% C 0.4 0.6	0.8 1 1.5
Previous (neo)adjuvant trastuzumab		With Without		•		
Treatment-free interval for previous adjuvant therapy		≥12 to <24 mo ≥24 months	nths	•		
https://bit.ly/bmj-	metabc		< Favor	urs interven ©	tion Favo 2023 BMJ Publi	ishing Group Lto

Thank you very much to the five students featured in this issue who were first to submit their visual abstracts!

The next five visual abstracts that are submitted to **surgo\_uofg@yahoo.com** by 15th May will receive **£20**.

To wrap up this academic year of Surgo, Prof. Matthew Walters has kindly offered to judge and decide on the best visual abstract submitted in this issue and our next issue of Surgo. The winner will receive **£100** prize money.

### What do I need to submit?

- Your written abstract (introduction, methods, results, conclusion (250 words))
- Your visual abstract
- The name of one project supervisor
- The date of submission to the competition

#### Good luck!

<sup>1.</sup> Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial BMJ 2023; 383 :e076065 doi:10.1136/bmj-2023-076065